MARKET

ABCL

ABCL

AbCellera Biologics Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.99
-1.18
-3.45%
After Hours: 32.60 -0.39 -1.18% 17:56 05/18 EDT
OPEN
33.87
PREV CLOSE
34.17
HIGH
34.00
LOW
32.60
VOLUME
659.48K
TURNOVER
--
52 WEEK HIGH
71.91
52 WEEK LOW
23.20
MARKET CAP
8.75B
P/E (TTM)
137.00
1D
5D
1M
3M
1Y
5Y
Aerpio Pharmaceuticals, Apellis Pharmaceuticals leads healthcare gainers; Shineco, Seelos Therapeutics among major losers
Gainers: Aerpio Pharmaceuticals ARPO +61%, Apellis Pharmaceuticals (APLS) +21%, Petros Pharmaceuticals PTPI +19%, Odonate Therapeutics (ODT) +11%, AbCellera Biologics (ABCL) +9%.Losers: Shineco (TYHT) -19%, Seelos Therapeutics SEEL -18%, CEL-SCI (CVM) -11%...
Seekingalpha · 1d ago
Lumina Fund Management LLC Buys Regeneron Pharmaceuticals Inc, Merck Inc, Viatris Inc, Sells ...
GuruFocus News · 1d ago
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Cut Their EPS Forecasts Substantially
The analysts covering AbCellera Biologics Inc. ( NASDAQ:ABCL ) delivered a dose of negativity to shareholders today, by...
Simply Wall St. · 2d ago
Sector Update: Health Care Stocks Rise Friday But Trail Most Other Sectors
MT Newswires · 4d ago
Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug
Investor's Business Daily · 4d ago
Credit Suisse Maintains Outperform on AbCellera Biologics, Lowers Price Target to $51
Credit Suisse analyst Tiago Fauth maintains AbCellera Biologics (NASDAQ:ABCL) with a Outperform and lowers the price target from $53 to $51.
Benzinga · 4d ago
Sector Update: Health Care Stocks Rising in Friday Afternoon Trade
MT Newswires · 4d ago
Premarket Movers: Plug Power, DoorDash, AbCellera Biologics
With U.S. stock markets set to open in two hours, (PLUG) was up 10.9% in pre-market trading, and (DASH) was up 9.1%. (MAT), (TT), and (HUBB) were all posting...
marketwatch.com · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABCL. Analyze the recent business situations of AbCellera Biologics Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABCL stock price target is 51.20 with a high estimate of 55.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 70.65M
% Owned: 26.64%
Shares Outstanding: 265.17M
TypeInstitutionsShares
Increased
19
3.71M
New
37
4.98M
Decreased
13
3.33M
Sold Out
18
2.82M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chief Executive Officer/Director
Carl Hansen
Co-Founder/Chief Operating Officer/Director
Veronique Lecault
Co-Founder
Kevin Heyries
Chief Financial Officer/Primary Contact
Andrew Booth
General Counsel
Tryn Stimart
Director
Peter Thiel
No Data
About ABCL
AbCellera Biologics Inc. is a biotechnology company, which offers drug discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. Its platform incorporates and integrates technology tools from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning and data science. The Company is engaged in the business of applying a multiple technology in its medical research and development to extract antibody-based drugs. Its solution allows to source, search, decode, engineer and deliver lead antibodies. The Company's solution allows to source, search, decode, engineer and deliver lead antibodies. The Company's subsidiaries include AbCellera Properties Inc., AbCellera Properties Columbia Inc., AbCellera US Holdings Inc., Channel Biologics Pty Ltd., Lineage Biosciences Inc. and Trianni, Inc.

Webull offers kinds of AbCellera Biologics Inc stock information, including NASDAQ:ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.